Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | hydroxysteroid (17-beta) dehydrogenase 10 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | 3-oxoacyl-[acyl-carrier-protein] reductase | hydroxysteroid (17-beta) dehydrogenase 10 | 252 aa | 251 aa | 24.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | microtubule-associated protein tau | 0.0736 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0069 | 0.0475 | 0.0418 |
Toxoplasma gondii | PAN domain-containing protein | 0.0329 | 0.4194 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0069 | 0.0475 | 0.0418 |
Loa Loa (eye worm) | carboxylesterase | 0.0069 | 0.0475 | 1 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0069 | 0.0486 | 1 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0736 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0069 | 0.0475 | 0.0418 |
Brugia malayi | Carboxylesterase family protein | 0.0069 | 0.0475 | 0.9745 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0039 | 0.0059 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0329 | 0.4194 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0069 | 0.0475 | 1 |
Mycobacterium tuberculosis | Probable short-chain type dehydrogenase/reductase | 0.0069 | 0.0486 | 1 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0065 | 0.0419 | 0.8661 |
Schistosoma mansoni | 3-hydroxyacyl-CoA dehydrogenase | 0.0069 | 0.0486 | 0.0429 |
Echinococcus multilocularis | tumor protein p63 | 0.036 | 0.464 | 0.4608 |
Brugia malayi | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0069 | 0.0486 | 1 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0039 | 0.0059 | 0.5 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0039 | 0.0059 | 0.5 |
Echinococcus multilocularis | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0069 | 0.0486 | 0.0429 |
Brugia malayi | Carboxylesterase family protein | 0.0069 | 0.0475 | 0.9745 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0053 | 0.025 | 0.0192 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0039 | 0.0059 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0039 | 0.0059 | 0.5 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0039 | 0.0059 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0069 | 0.0475 | 0.0418 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.025 | 0.4584 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0069 | 0.0486 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.0475 | 1 |
Onchocerca volvulus | 0.0053 | 0.025 | 0.5 | |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0039 | 0.0059 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.0475 | 1 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0069 | 0.0475 | 0.0418 |
Echinococcus multilocularis | acetylcholinesterase | 0.0069 | 0.0475 | 0.0418 |
Echinococcus multilocularis | acetylcholinesterase | 0.0069 | 0.0475 | 0.0418 |
Leishmania major | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0069 | 0.0486 | 1 |
Echinococcus granulosus | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0069 | 0.0486 | 0.0429 |
Echinococcus granulosus | tumor protein p63 | 0.036 | 0.464 | 0.4608 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0039 | 0.0059 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 5.0119 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 29.9349 uM | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.